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Abstract 
Objective: Intravaginal exposure to simian immunodeficiency virus (SIV) acutely recruits 
interferon-alpha (IFN-α) producing plasmacytoid dendritic cells (pDC) and CD4+ T-lymphocyte tar-
gets to the endocervix of nonhuman primates. We tested the impact of repeated cervicovaginal ex-
posures to noninfectious, defective SIV particles over 72 hours on a subsequent cervicovaginal 
challenge with replication competent SIV. Methods: Thirty-four female Indian Rhesus macaques were 
given a 3-day twice-daily vaginal exposures to either SIVsmB7, a replication deficient derivative of 
SIVsmH3 produced by a T lymphoblast CEMx174 cell clone (n = 16), or to CEM supernatant controls  
(n = 18). On the fourth day, animals were either euthanized to assess cervicovaginal immune cell 
infiltration or intravaginally challenged with SIVmac251. Challenged animals were tracked for 
plasma viral load and CD4 counts and euthanized at 42 days after infection. Results: At the time of 
challenge, macaques exposed to SIVsmB7, had higher levels of cervical CD123 pDCs (P = 0.032) and 
CD4+ T cells (P = 0.036) than those exposed to CEM control. Vaginal tissues showed a significant 
increase in CD4+ T-cell infiltrates (P = 0.048) and a trend toward increased CD68+ cellular infiltrates. 
After challenge, 12 SIVsmB7-treated macaques showed 2.5-fold greater daily rate of CD4 decline (P 
= 0.0408), and viral load rise (P = 0.0036) as compared with 12 control animals. Conclusions: Repeated 
nonproductive exposure to viral particles within a short daily time frame did not protect against 
infection despite pDC recruitment, resulting instead in an accelerated CD4+ T-cell loss with an in-
creased rate of viral replication. 
 
Keywords: simian immunodeficiency virus, nonhuman primate, CD4, plasmacytoid dendritic cells, 
cervicovaginal mucosa 
 
Introduction 
 
Women comprise over half of all individuals living with HIV-1 worldwide with intravag-
inal sex as the predominant route of transmission.1 However, the rate of infection among 
exposed females is statistically low, indicating that only a fraction of viral exposures result 
in productive infection.2–5 At each exposure, HIV can interact with the cervical epithelium6,7 
mediating cellular infiltration6,8 and potentially engaging Toll-like receptor (TLR) 7 on den-
dritic cells.8–10 The effects of nonproductive HIV-1 or simian immunodeficiency virus (SIV) 
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cervicovaginal exposures (absent infection) on subsequent infection outcomes remain un-
clear. 
The CAPRISA004 trial found a positive association between a preexisting inflammatory 
cytokine profile within cervicovaginal fluids and subsequent HIV infection,11 supporting 
previously held views that vaginal immune activation increases HIV-1 infectivity. In par-
allel, a study examining SIV infectivity in rhesus macaques after direct topical application 
of TLR-7/9 ligands to the cervicovaginal mucosa showed increased localized inflammation 
and increased viral load after challenge.12 However, there are well-documented cases of 
women with a history of chronic multiyear HIV-1 exposure without infection indicating 
that exposure-initiated mechanisms may reduce future infectivity on reexposure.13–15 Of 
interest, studies of resistance in these women have largely failed to identify HIV-specific 
responses as a determinant of protection15 but a loss of HIV-1 “resistance” in a subset of 
these women after reduced sex work (i.e., HIV-1 exposure) has suggested that resistance 
is sustained by innate rather than adaptive responses.16 
Acute cellular changes after cervicovaginal mucosal infection have been studied. Infec-
tion is established within CD4+ T cells and other permissive cells of the lamina propria17–20 
following a robust cellular infiltrate of plasmacytoid dendritic cells (pDCs) and CD4 T 
cells,6 and increased mRNA expression of proinflammatory cytokines/chemokines by day 
3 post infection (DPI).21 Of interest, Li et al. demonstrated that infiltrating cervical pDCs 
produce interferon-alpha (IFN-α) within hours of SIV exposure, preceding CD4+ T-cell in-
filtrates by 72 hours.6 
The anti-HIV properties of pDCs and type I IFN have been documented and involve 
intrinsic and secondary antiviral mechanisms, such as the induction of tetherin or APOP-
BEC family members, and the modulation of innate and adaptive effectors.22–27 In a recent 
clinical study in individuals with chronic HIV infection, IFN immunotherapy sustained 
viral suppression during antiretroviral therapy interruption in a subset of subjects sup-
porting the interpretation that IFN can inhibit HIV-1 production/replication.28 However, 
the role of infiltrating pDCs as a source of type I IFNs and its impact on acute SIV infection 
if present before infection as a result of repeated noninfectious viral exposures remains 
unclear. Taking advantage of a replication-deficient SIVsmB7 clone derived from 
SIVsmH3, able to bind CD4 and fuse with its target without subsequent viral replication,29–
31 we tested the hypothesis that repeated vaginal exposures to SIV in the absence of pro-
ductive infection would decrease viral infection potential and/or decrease replication ki-
netics as a consequence of sustained cervical pDC infiltration despite the increase in local 
CD4+ T-cell infiltrates. 
 
Methods 
 
Ethics Statement and Animal Procedures 
Healthy Indian Rhesus monkeys (Macaca mulata) were acquired from the Caribbean Pri-
mate Research Center of the University of Puerto Rico (UPR)—Medical Sciences Campus 
(MSC). Animals were quarantined for 6 months and maintained at the AAALAC-accred-
ited facilities of the Animal Resources Center, UPR-MSC. 
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All animal studies were approved by the UPR-MSC, Institutional Animal Care and Use 
Committee (IACUC), and comply with the Guide for the Care and Use of Laboratory An-
imals. Animal Welfare Assurance number: A3421, Protocol number: 3380308. 
In addition, steps were taken to reduce suffering in accordance with the recommenda-
tions of the Weatherall report, “The Use of Nonhuman Primates in Research.” For instance, 
all procedures were conducted under anesthesia by using ketamine 10–20 mg/kg, deliv-
ered intramuscular. 
Phase I: 10 (6 and 4) macaques were given either intravaginal SIVsmB7 or CEM mock 
control inoculations. Inoculations were given twice daily for 3 days in either the follicular 
or luteal phase, as shown in figure 1 and figure S1 (see the supplemental content following 
the references). Macaques were euthanized on the fourth day. 
 
 
 
Figure 1. Phase I/II criteria. The study was separated into 2 separate phases. Ten macaques 
were used in phase I: 4 CEM mock control intravaginally inoculated animals and 6 
SIVsmB7 intravaginally inoculated animals. These animals were used to assess cellular 
infiltration in the cervical and vaginal epithelium. For phase II, 24 animals were divided 
equally either into CEM mock control– or SIVsmB7-inoculated animals. The inoculation 
sequence for phase I was repeated and SIVmac251 challenge. 
 
Phase II: Female macaques were housed together before use in the study to allow the 
animals to reach menstrual synchrony. Twenty-four macaques, 12 macaques per group, 
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were given either intravaginal SIVsmB7 or CEM mock control inoculations (table 1 and fig. 
1). Inoculations were given twice daily for 3 days during the luteal phase. On the fourth 
day after inoculation, each macaque was given a single 1 mL challenge dose SIVmac251. 
Blood was taken before the challenge and on days 7, 14, 21, and 42 to determine plasma 
viral load and CD4 count. Macaques were euthanized on days42–46 based on the analysis 
focused on early viral kinetics after a single exposure and infection. 
 
Table 1. Baseline Parameters at the Time of Challenge for Phase II Animals 
 CEM Mock Control Treated 
(12 Macaques) 
SIVsmB7 Treated 
(12 Macaques) Pa 
Age (yrs) 5.0 (4–10) 4.0 (3–6) 0.0249 
Weight (kg) 5.43 (3.86–11.05) 5.11 (4.26–6.24) 0.2603 
Day of challengeb 41.58 (25–62) 38.50 (24–62) 0.8172 
CD4 count (cells/mL) 733.0 (449.0–1085) 768.0 (602.0–1379) 0.1749 
CD8 count (cells/mL) 397.5 (218.0–800) 380.0 (198.0–799.0) 0.8174 
Estrogen (pg/mL)c 80.5 (37.50–149.0) 75.85 (20.0–309.0) 0.8399 
Progesterone (ng/mL)c 4.75 (1.03–8.44) 3.855 (0.97–8.19) 0.9540 
Estrogen: progesterone (ratio) 21.94 (7.603–49.19) 20.82 (7.12–55.16) 0.8399 
Median values shown (interquartile range). 
a. P values assessed using Wilcoxon rank-sum tests. 
b. Calculated from time after January 1, 2011 to signify equal timing from the start of the study year. 
c. Measured at day of challenge. 
 
Euthanasia was performed only on fully anesthetized animals by injection of pentobar-
bital sodium at 390 mg/mL; 1 cc/10 lbs IV. Vaginal and cervical tissues were taken for anal-
ysis. 
 
Viruses 
SIVmac251 was diluted 1:2 from a 20,000 TCID50 per milliliter viral stock grown in specific 
pathogen free rhesus macaque peripheral blood mononuclear cell produced by Dr. Ron 
Desrosiers (New England National Primate Research Center, Harvard Medical School) and 
kindly provided by Dr. Nancy Miller (NIAID) through contract #N01-AI-30018. Animals 
were challenged with 1 mL of the diluted viral stock. In vivo, titration was performed as 
described in the Supplemental Methods. 
SIVsmB7 is a virus-like particle derived from a clone of a CEMx174 cell line stably in-
fected with SIVsmH3. SIVsmB7 is noninfectious because of a 1.6 kbp deletion, including 
integrase, vif, vpr, and vpx genes. Cell-free SIVsmB7 and CEMx174 supernatant (CEM mock 
control) were isolated by standard 20% (wt/vol) sucrose gradient ultracentrifugation. P27 
enzyme-linked immunosorbent assay was used to determine 500 µg P27 SIVsmB7 dose. 
CEMx174 dose was established by equal protein quantification with SIVsmB7 dose. 
 
CD4 and CD8 Counts 
CD4 and CD8 counts were monitored by TruCount Absolute Count Kits (BD Bioscience, 
San Jose, California) used according to manufacture protocol. 
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SIV Viral Loads 
Plasma viral load was assessed by quantitative reverse transcriptase-polymerase chain re-
action as previously described.32 Full method can be found in the Supplemental Methods. 
Immunohistochemistry 
Samples from the vagina and cervix were harvested postmortem from each animal and 
fixed in 4% paraformaldehyde and embedded in paraffin for sectioning, SafeFix II (Fisher 
Scientific, Pittsburgh, PA), or frozen. Immunohistochemical staining for CD123, CD68, 
CD4, and Mx1 was conducted as previously reported6 (For complete method, see Supple-
mental Methods, http://links.lww.com/QAI/A482). CD123+ cells were considered pDC as a 
previous report by Li et al6 has shown that CD123+ cells infiltrating into the endocervical 
subepithelium 3 days after SIV exposure stain positive for both HLA-DR and IFN-α con-
firming these cells are pDC. 
 
Statistical Analysis 
Cross-sectional phase 1 and phase 2 two group comparisons between SIVsmB7-exposed 
and CEM mock control–inoculated animals were made using Wilcoxon rank-sum tests, 
Fisher test or Student t tests. Two-tailed P values less than 0.05 were considered statistically 
significant. 
To evaluate the rate of change for LogVL and CD4, a change-point model with random 
intercept terms for each monkey and fixed effects for baseline CD4, days-postinfection 
(DPI) (overall and after 14 DPI), a group indicator for SIVsmB7 exposure, and 2-way inter-
action terms between DPI and group, was fitted. This model accounts for the within indi-
vidual correlation in repeated measurements and allows for a different slope before and 
after 14 DPI. The models are listed below, with model variables estimates described in the 
results. The function (DPI–14)+ = 0 when DPI ≤ 14 and (DPI–14)+ = DPI–14 when DPI > 14. 
 
Model Equations for SIVsmB7 or CEM-Inoculated Animals 
 
 
Statistical analysis was performed using R 2.14.1 and Prism. 
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Results 
 
Phase I: Acute Cellular Infiltrates after 72 Hours of SIVsmB7/CEM Mock Control Expo-
sure 
Ten female macaques followed during their natural luteal or follicular phases were used 
to initiate 3-day twice-daily SIVsmB7/CEM mock control dosing within a 3-day period af-
ter the start of a menstrual phase (as exemplified for 2 luteal-staged animals in fig. S1 in 
the supplemental content). Animals were inoculated with CEM mock or SIVsmB7 as de-
scribed in figure 1 and in the methods. 
Consistent with previously published data showing that infectious SIV exposure re-
sulted in acute endocervical pDC and CD4+ T-cell infiltration within 3 days of SIV expo-
sure/infection,6 replication-deficient SIVsmB7-treated animals had a significant higher 
number of endocervical CD123+ pDC (P = 0.0317, mean: 1328 cells/mm2 vs. 435 cells/mm2) 
and CD4 T cells (P = 0.0357, CD4 mean: 141.2 cells/mm2 vs. 17.92 cells/mm2) as compared 
with CEM mock control–inoculated animals at 72 hours (fig. 2A) irrespective of hormonal 
phase. Moreover, in animals exposed to SIVsmB7, we detected a trend in increased expres-
sion of Mx1 (an IFN-stimulated gene; fig. 2A) localized in areas enriched for CD123+ cells. 
This is consistent with recruitment of CD123+ pDCs to the endocervix and local production 
of type I IFNs. Although exposure to SIVsmB7 did not result in increased vaginal pDC 
infiltration (fig. 2B), it did result in higher levels of CD4+ cells in vaginal tissues (fig. 2B; P 
= 0.0476; mean, 164.8 cells/mm2 vs. 37.95 cells/mm2). Similar to pDCs, SIVsmB7-treated an-
imals had higher (although not statistically significant) levels of CD68 macrophages than 
control animals in the cervix, but not in the vaginal tissue. Altogether, results confirm that 
exposure to replication-deficient SIV can modulate the tissue microenvironment, allowing 
us to directly test how these local viral-induced changes (i.e., pDC and CD4 T-cell infil-
trates) would impact a challenge with infectious SIVmac251. 
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Figure 2. Infiltrate staining and quantification of cervico-vaginal tissue taken from 
SIVsmB7 and CEM mock control–treated animals. A, Endocervix (top panel: CD123 stain-
ing 20×·image); SIVsmB7 treatment (left) induced large-scale pDC infiltration with cells 
directly underneath or near the columnar epithelium as compared with mock control (P 
= 0.0317) (second panel: Mx1 staining 20× image); corresponding with increased pDC in-
filtration in SIVsmB7-treated macaques, there were increased levels of interferon respon-
sive gene product (ISG) Mx1 in treated macaques compared with controls (third panel: 
CD4 staining 20×·image); SIVsmB7 treatment (left) induced moderate infiltration of CD4+ 
T cells as compared with CEM mock treatment (P = 0.0357) (bottom panel: CD68 staining 
20×·image); SIVsmB7 treatment (left) did not induce a significant increase in macrophage 
infiltration as compared with CEM mock control (right), but visually, macrophages ap-
peared closer to, and in some cases, permeated the columnar epithelium, suggesting a 
trend of increased infiltration (P = 0.0952). B, Vagina (top panel: CD123 staining 20× im-
age); SIVsmB7 treatment (left) induced no noticeable level of pDC infiltration as com-
pared with CEM mock control–treated animals (bottom) (P = 0.2000) (middle panel: CD4 
staining 20× image); SIVsmB7 treatment (left) induced a sizable increase in CD4 T-cell 
staining, with many positive staining cells found directly underneath the striated vaginal 
epithelium and comparably fewer cells found in the vaginal mucosa of CEM mock con-
trol–treated animals (right) (P = 0.0476) (bottom panel: CD68 staining 20× image); ma-
caques had moderate levels of macrophage staining within the vaginal mucosa regardless 
of treatment. This level of CD68 staining was not impacted by treatment (P = 0.3524). Pair-
wise comparisons were performed with Wilcoxon rank-sum tests. 
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Phase II: Outcome of SIVmac 251 Infection after 72-Hour Preconditioning with SIVsmB7 
or CEM Control 
Twenty-four female macaques were challenged with SIVmac251 after undergoing 72-hour 
exposure (as described above) to either SIVsmB7 (n = 12) or CEM control (n = 12). The 
groups were similar in weight and inoculation date relative to menstrual cycle (table 1; see 
fig. S2 in the supplemental content), and there was no significant difference in major his-
tocompatibility complex (MHC) class I allele distribution (Fisher exact test, P > 0.05) or for 
those associated with spontaneous control between groups33–35 (see table S1 in the supple-
mental content). 
Endogenous estrogen levels at the time of challenge between SIVsmB7 and CEM mock 
control arms were not significantly different (P = 0.84) (table 1), indicating the absence of 
differences in estrogen-related structural epithelial factors known to impact viral infectiv-
ity.36–38 
As it has been shown that cervicovaginal inflammation is common among captive rhe-
sus macaques,39 a 28-plex nonhuman primate luminex assay was performed within 1 week 
of challenge to assess levels of proinflammatory mediators in cervicovaginal lavages (CVL) 
in 13 of the 24 macaques (6 SIVsmB7/7 CEM mock). Twelve of the cytokines/chemokines 
tested were below the limit of detection and no cytokine/chemokine tested showed any 
significant difference between groups. Results for selected cytokines and chemokines are 
summarized in figure S3 (see supplemental content). 
Following a single, intravaginal SIVmac251 challenge using an infectious dose previ-
ously determined through an intravaginal titration (see Supplemental Methods), all 24 ma-
caques became infected, with a detectable viral load within 7 or 14 days postinfection (DPI) 
(fig. 3B). Viral load peaked in all animals by 14–21 DPI, with a mean viral load of 6.63 and 
8.02 for CEM mock control– and SIVsmB7-treated, respectively (Student t test: P = 0.0720). 
Although we didn’t detect a significant difference in peak viral load, there was a trend 
toward increased viral load in SIVsmB7-treated macaques as compared with CEM mock–
treated animals (fig. 3B). We did detect a statistically significant decline in CD4+ T cells at 
14 DPI in SIVsmB7-treated macaques as compared with control animals (Student t test: P 
= 0.0268, mean: –355.8 CD4/µl vs. CEM—120.4 CD4/µl) (fig. 3D) consistent with a more 
severe CD4 depletion after infection in the SIVsmB7-treated females. Notably, 4 of the ma-
caques in the control group (animals 8D4, M847, 31R, and 530) had lower plasma viral 
loads. These animals were similar to the other animals in the control and experimental 
groups in terms of MHC genotypes, batch of doses used, day of manipulation, estrogen 
levels, weight, age, and history of parity (data not shown). Analysis of baseline CVL sam-
ples from 2 of these macaques, 53O and 31R, showed no difference to other infected control 
macaques. 
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Figure 3. Change-point model of log plasma viral load (LogVL) and CD4 for phase II ma-
caques. A, ∆CD4 for SIVsmB7-treated macaques was significantly higher than in CEM 
mock control. By 14 DPI, there was mean loss of –355.8 CD4 per microliter in SIVsmB7-
treated animals compared with –120.4 CD4 per microliter for controls [Student t test; P = 
0.0268 (inset)]. B, Twenty-two of 24 macaques in both treatment arms reached peak viral 
load on days 14 or 21. Four of the CEM macaques had significantly lower log viral loads 
than the remaining 8 CEM mock macaques (t test on area under curve with P < 0.0001), 
which was not explained by known correlates of spontaneous SIV control or protection 
suggesting low viral load was normal variation. At no time point was difference in Log 
viral load significant; however, starting at 14 DPI and ending at 42 DPI, there was a trend 
toward increased viremia in SIVsmB7-inoculated macaques (Student t test; P = 0.118). C, 
As we detected a significant difference in ∆CD4 between groups, we generated a linear 
mixed effect spline model to investigate CD4 change between treatment groups over time 
(in days, as “DPI”). This model predicts an increased loss of CD4+ T cells per day of 14.5 
cells per microliter over top of the CEM mock control animals culminating at peak viremia 
(day 14). D, To investigate the behavior of log viral load, a linear mixed effect spline model 
for LogVL was also generated. The LogVL model predicts SIVsmB7-treated animals to 
have an increased log viral load rise per day of 0.106 over top of CEM mock–treated ani-
mals up until peak viremia on day 14. 
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Model of Log Viral Load Rise and CD4 Decline in Phase II Macaques 
As our data detected that SIVsmB7 exposures before an infectious challenge caused a sig-
nificant decline in CD4 at peak viral load after infection, we generated linear models for 
CD4 or log viral load kinetics over days (DPI) and included a spline (or change-point) at 
peak viral load day 14 representing the end of the acute change in variables after infection 
(illustrated in both viral load and CD4 decline data in figs. 3C, D). As expected, both mod-
els showed that (1) DPI is a significant determinant of both CD4 decline and viral load rise 
for animals in either group as exemplified by its coefficient β3 in control (P = 0.0436 for CD4 
and P < 0.0001 for logVL; Methods and table 2) and β3′ in SIVsmB7 treated (P = 0.0408 for 
CD4 and P = 0.0036 for logVL) and (2) day 14 is a valid change-point as illustrated by the 
reverse of direction of estimates for β3 and β4 for the control and β3′ and β4′ for the SIVsmB7 
group. 
The model for CD4 T-cell kinetics closely approximated our CD4 data and indicated a 
significantly different change rate between groups before day 14 (β3′, P = 0.0408; fig. 3 and 
table 2). The effect of infection in the CEM mock control animals showed a loss of 10.06 
CD4+ T cells per microliter each day until peak viremia (140.8 loss at peak viral load). 
SIVsmB7-treated macaques had a 2.5-fold higher daily loss of CD4+ T cells totaling 25.0 
CD4+ T cells per microliter per day (342.8 loss at peak viral load). 
As for viral load, the model showed a significantly higher rate of change in viral load 
for the SIVsmB7 over CEM control before day 14 (β3′, P = 0.0036; fig. 3 and table 2) in sup-
port of greater CD4 T-cell loss. Specifically, log viral load rise each day after infection was 
predicted to be 0.553 log per day in SIVsmB7-treated macaques as compared with 0.446 
log per day for CEM mock control animals. Taking into account baseline CD4 count, CD8 
count, CD4/CD8 ratio, age, or weight, as independent factors did not change the model’s 
output for viral load rise. 
All together, our results suggest that noninfectious SIV exposures and associated con-
ditioning of the local microenvironment result in a greater CD4+ T-cell decline with higher 
viral load. 
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Table 2. Intercept and Model Coefficients for CEM Control Versus SIVsmB7-Treated Macaques 
from Phase II* 
Coefficients for LogVL 
Change-Point Models Estimate Standard Error P 
β0 2.340666 1.564118 0.1373 
β1 –0.13222 0.172551 0.4525 
β2 –0.00176 0.001144 0.1396 
β3 0.446266 0.025321 <0.0001* 
β4 –0.48223 0.034106 <0.0001* 
β0′ –0.1968 0.684871 0.7768 
β3′ 0.106337 0.035784 0.0036* 
β4′ –0.1141 0.048224 0.0197* 
Coefficients for CD4 
Change-Point Models Estimate Standard Error P 
β0 323.5255 203.569 0.1147 
β1 –34.6649 22.16708 0.1336 
β2 0.8501 0.14663 <0.0001* 
β3 –10.0638 4.93237 0.0436* 
β4 11.3498 6.64368 0.0903 
β0′ –7.7609 99.82471 0.9388 
β3′ –14.4239 6.97048 0.0408* 
β4′ 19.3415 9.39395 0.0418* 
*Denotes significant coefficients in the model. 
 
Discussion 
 
We show for the first time that an early, local, innate, and CD4 T-cell response to replica-
tion-deficient SIV particles can enhance the rate of CD4+ T-cell decline and viral load rise 
on a subsequent productive infection. Our results were contrary to our original hypothesis 
that the observed increase in SIV-induced cervical pDC infiltrates and local IFN-mediated 
mechanisms would inhibit productive infection. Instead, our data are consistent with viral 
exposures acutely modulating levels of vaginal and cervical CD4+ T-cell infiltrates, provid-
ing a greater preexisting “substrate” for viral infection, potentially overwhelming any in-
hibition provided by pDC and resulting in an accelerated decrease of CD4+ T cells in 
association with viral replication. Importantly, our data assessing the impact of recruited 
pDC were collected during natural progesterone high periods independent of pharmaco-
logical treatments commonly used to synchronize animals as these have been shown to 
impair pDC function.40,41 
Our results parallel a report by Wang et al. where female macaques were preexposed to 
TLR-9 or TLR-7 ligands, CpG, or imiquimod, respectively, before and during SIVmac251 
challenge.12 Wang et al. did not quantify differences in cellular infiltrates before challenge 
nor model viral kinetics to peak viral load, but did observe increased inflammatory cyto-
kines and infiltrate after dosing and a higher viral load 8 weeks after infection. Their re-
ported data are consistent with our observed accelerated CD4 loss and viral load rise in 
SIVsmB7 pre-exposed animals. We speculate that the Wang et al. study showed a more 
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marked increase in viral replication than our study due to use to 2 challenges using a 
SIVmac251 one log higher (greater viral inoculum42) and use of optimized TLR-7/9 lig-
ands, which may have induced a greater inflammatory environment (greater local immune 
activation43). 
Importantly, our results are directly relevant to both low-dose SIV repeated challenge 
study designs commonly used in vaccine studies and to settings of repeated HIV exposures 
in women. Regarding SIV study designs, our data suggest that early SIV challenges may 
encounter a different microenvironment than later challenges as a result of immune cell 
infiltration. Infections after repeated exposures may increase local cell targets and result in 
accelerated infection kinetics and/or greater gut-associated lymphoid tissue depletion 
when compared with infections occurring at the start of exposures. Per human cohorts, 
our data suggest that a sex worker in an area with high HIV-1 prevalence may have differ-
ent levels of intravaginal immune cell infiltration, independent of coinfections, as com-
pared with women with low levels of HIV-1 exposure. The presence of increased CD4+ T 
cells and CD68 cells in women at higher risk of HIV-1 infection or in nonhuman primates 
after multiple SIV exposures may decrease the efficiency of prophylactic interventions by 
increasing infection efficiency. However, it would be of interest to determine if vaccine-
elicited antiviral antibodies in the presence of an increase in cellular infiltration could also 
provide a greater effector population to harness potentially protective antibody-depended 
cell-mediated cytotoxicity mechanisms in high-risk uninfected women. Taken together, 
our data suggest that SIV/HIV exposures can contribute to local immune modulation af-
fecting the host tissue response to future viral infection as already established for other 
STD coinfections.4,16,44,45 Future experiments using a lower infectious dose or repeated low 
to high-dose escalation of virus would be needed to directly show if SIVsmB7 preexpo-
sures would increase infection rate over controls as suggested by our data. 
Our study had limitations that we addressed. First, our replication-deficient virus, 
SIVsmB7, was derived from the human cell line, CEMx174. Previous studies have shown 
that xeno/allogeneic adaptive immune responses to MHC alone can block infection.46 We 
found that both SIVsmB7 and CEMx174 supernatants had MHC class I and class II proteins 
(see fig. S4 in the supplemental content). The 72-hours time frame used for this experiment 
would limit development of adaptive xenoantigenic responses; moreover, we used a chal-
lenge virus derived from a rhesus macaque cell line to avoid this possible confounder re-
sponse (Methods). It has been shown that innate allogenic responses can be rapid in 
response to live tissue grafts,47 yet little is known about the speed and strength of such 
responses through mucosal administration of MHC proteins. Mucosal studies to date have 
only examined such responses after the induction of the adaptive response.48,49 We inter-
pret that because MHC proteins are present in both SIVsmB7 and control, it is unlikely 
there would be a differential response yet to be detected based on MHC alone. Importantly, 
CD4+ T-cell and pDC infiltration was significantly greater in SIVsmB7-treated animals in-
dicating the control proteins did not induce change in the absence of SIV proteins. As for 
other proteins shown in figure S4 and table S2 (see the supplemental content), proteomic 
analysis of both CEM mock and SIVsmB7 doses had comparable protein content to 
SIVsmB7 outside the presence of viral proteins or Mov10. Interestingly, the presence of 
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Mov10 (see table S2 in the supplemental content) in SIVsmB7 proteomic analysis is con-
sistent with enriched particle generation, as previous reports have shown that Mov10 in-
corporates into viral particles.50 It has also been shown that ectopic expression of Mov10 is 
an inhibitor of HIV-1/SIV infectivity50–53; however, our data together with a recent report 
showing that basal levels of Mov10 had no impact on HIV-1 replication or infectivity ar-
gues against its antiviral potential.51 
Second, previous studies have shown that captive rhesus macaques can have divergent 
preexisting cervicovaginal inflammation.39,54 To control for this, we did random testing of 
CVL from rhesus macaques and found no difference in inflammatory cytokine levels be-
tween treatment groups (see fig. S3 in the supplemental content) despite observing differ-
ential CD4 changes between groups as described. The only difference we did detect was a 
1-year difference in age between groups (table 1). We do not expect this minor difference 
impacts our data as previous research has evidenced no significant difference in immune 
parameters, such as immune activation or serum cytokine level, among young to middle-
age macaques.55 
Third, our conclusions address the cervicovaginal mucosa and not other mucosal routes 
of exposure. Future studies will need to establish whether repeated replication-deficient 
rectal exposures induce CD4+ T-cell infiltration and affect the severity of a productive in-
fection. Intriguingly, sustained SIV-resistance has been reported following repeated low-
dose intra-rectal SIV challenges, highlighting a potential difference in compartments or 
difference between 72 hours versus chronic exposure effects or both.56 
In conclusion, our data support a model where viral exposures in the absence of pro-
ductive infection induce changes in cervicovaginal cellular infiltrates that do not prevent 
infection. Furthermore, our data may indicate an added risk to repeated short-term expo-
sures not previously identified and introduces an unaccounted tissue change variable that 
may impact the outcome of SIV challenge in studies evaluating protection by low-dose 
repeated challenge formats using female macaques. 
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Supplemental Digital Content – Methods 
 
SIVsmB7 and CEMx174 Proteomic Analysis 
 
SDS-PAGE Gels 
20 µl of B7 and CEM each were loaded to a 12% NuPage 1-mm-thick gel. The gel was 
stained with Invitrogen Colloidal Coomassie Blue stain. 
 
Protein Digestion 
Selected bands were excised from the gel and subsequently destained using 200 µl of 200 
mM ammonium bicarbonate and 50% acetonitrile for 30 min with shaking at 37°C and then 
dried in a SpeedVac. This was followed by reduction/alkylation of the protein band by 
adding 100 µl 20 mM TCEP in 25 mM ammonium bicarbonate at pH 8.0, incubated for 15 
min at 37°C with shaking. The supernatant was discarded and 100 µl of 40 mM iodoa-
cetamide in 25 mM ammonium bicarbonate at pH 8.0 was added and incubated for 30 min 
at 37°C with shaking. The supernatant was again discarded and two subsequent washes 
of 200 µl 25 mM ammonium bicarbonate were done for 15 min each with shaking. A final 
wash was done under the same conditions, except 50% acetonitrile, 25 mM ammonium 
bicarbonate was used for the wash. The bands were dried in the SpeedVac and were then 
rehydrated with 20 µl of 0.02 µg/µl modified Trypsin (Promega) in 40 mM ammonium 
bicarbonate overnight with shaking at 37°C. The next morning, the supernatant was re-
moved to a clean tube on ice and 20 µl of 40 mM ammonium bicarbonate was added to the 
gel piece for 30 min with shaking at 37°C. The supernatants were combined and 4 µl of 
neat acetic acid were added to stop the digest. 
 
Protein Identification 
4 µls of the combined digest were injected onto a nanocapillary reverse-phase column (self-
packed, New Objective 75 um column terminating in a nanospray 15 um tip) directly cou-
pled to a ThermoElectron Orbitrap mass spectrometer. A top six method was used to ob-
tain MS and MS/MS data. A customized database was created using a Simian database 
with common contaminants and bovine (tagged) added. The database was indexed for 
partial tryptic searching and the resulting masses and MS/MS spectra from the Orbitrap 
were searched against this database using the SEQUEST search engine [1, 2]. Subsequent 
data were filtered using 5 ppm, delta cN of 0.07. Results were reported as spectral counts. 
 
Hormone Measurements 
Blood was taken every other day between days 7–23 of the menstrual cycle. Estradiol and 
progesterone concentrations were measured by enzyme-amplified chemiluminescence 
(Immulite 1000, Siemens). The analytical limits of sensitivity of the estradiol and proges-
terone assays were 15 pg/mL (references range of 20–2,000 pg/mL) and 0.1 ng/mL (refer-
ence range of 0.2-40 ng/mL), respectively. 
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Immuno-histochemistry 
Tissues were deparaffinized and rehydrated in deionized water. Heat-induced epitope re-
trieval was performed using the water-bath method (95–98°C for 10–20 min) in 10 mM 
sodium citrate, pH6.0 for CD123 detection (Sc-681, 1:2000, Santa Cruz Biotechnology Inc.), 
and Mx1 (1:3000, ProteinTech) and CD68 (KP1, 1:200, Dako). For CD4 detection (IF6, 1:60, 
Leica Microsystems), epitope retrieval was performed using high-pressure Decloaking 
Chamber (121°C for 35 sec, Biocare Medical) in 1 mM EDTA, pH 8.0, followed by cooling 
to room temperature. Tissue sections were blocked with SNIPER Blocking Reagent 5% 
Non-fat milk (Biocare Medical) for 1 hr at room temperature. Endogenous peroxidase was 
blocked with 3% (v/v) H2O2 in methanol TBS (pH7.4) 3% [v/v] for CD68, Mx1 and CD123, 
and 0.9% for CD4 detection). Primary antibodies were diluted in 10% SNIPER Blocking 
Reagent in TNB blocking buffer (Tris-HCl, pH7.5, 0.15M NaCl, 0.05% Tween 20 with 0.5 
Dupont blocking reagent buffer) and incubated overnight at 4°C. After the primary anti-
body incubation, sections were washed and then incubated with mouse, goat, or rabbit 
polymer system reagents conjugated with either horseradish peroxidase or alkaline phos-
phatase (ENVISON kit; Dako) according to the manufacturer’s instructions, and devel-
oped with 3,3′-diaminobenzidine (Vector Laboratories). Sections were hematoxylin 
counterstained, mounted in Permount (Fisher Scientific), and examined by light micros-
copy. Non-specific, IgG was used as isotypic control. 
Whole sections of each stained slide were digitized using Scanscope (Aperio), the image 
was opened in ImageScope, and endocervical areas were selected with ImageScope draw-
ing tools for analysis. CD4+, CD68+, Mx1+ or CD123+ cells were quantified by using a pos-
itive pixel count algorithm in the Spectrum Plus analysis program (Version 9.1, Aperio). 
The parameters of the algorithm were manually tuned to match the specific staining 
markup image accurately over background DAB stain. Once the parameters were set, the 
algorithm was applied automatically to all digital slides to measure the number of cells of 
interest. Data were reported as positive staining cells per square millimeter. 
 
DNA Isolation and MHC Genotyping 
Genomic DNA was isolated from a maximum of 3.0 × 106 peripheral blood mononuclear 
cells using the MagNA Pure LC system (Roche Applied Science) and the MagNA Pure LC 
DNA Isolation–Large Volume protocol (version 3.0) according to manufacturer’s guide-
lines. The elution volume of extracted DNA was 200 µl of MagNA Pure LC DNA Isolation–
Large Volume elution buffer. DNA concentrations (ng/µl) and Abs 260 nm/Abs 280 nm 
ratios were determined using a NanoDrop UV Spectrophotometer (NanoDrop Technolo-
gies). Genotyping for Mamu-A*01, A*02, A*08, A*11, B*01, B* 03, B*04, B*17, B*08, and 
DRBw*201 was done as previously described [3–5]. 
 
Viral Load 
Plasma samples were spiked with armored RNA (aRNA; Asurgen) and centrifuged at 
25,000 x g for 1 h. Viral RNA (vRNA) was extracted from the pellet with Proteinase K (2.5 
µg/µl; Life Tech) and the High Pure Viral RNA kit (Roche). Eluted vRNA (100 µl) was then 
subjected to the RNA Clean and Concentrator kit (ZYMO Research) and eluted in 50 µl, 
from which 15 µl were reverse transcribed using MultiScribe™ Reverse Transcriptase (Life 
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Tech) in a 50-µL gene-specific reaction. Fourteen microliters of cDNA were added to Taq-
Man gene expression master mix (Life Tech), along with primers and a probe targeting the 
gag region of SIVmac251, and subjected to 40 cycles of qPCR analyses. Fluorescence signals 
were detected with an Applied Biosystems 7900HT Sequence Detector. Data were captured 
and analyzed with Sequence Detector Software (Life Tech). Viral copy numbers were cal-
culated by plotting CT values obtained from samples against a standard curve generated 
with in vitro-transcribed RNA representing known viral copy numbers. The limit of detec-
tion of the assay was five copies per reaction volume or 40 copies per ml of plasma. 
 
SIVmac251 Titration 
Infectious challenge was carried out with SIVmac251. The infectious dose via intravaginal 
delivery was independently determined in a titration study on 15 female rhesus macaques 
upon vaginal challenge preceding our study. Macaques were intravaginally inoculated 
with either a single dose of undiluted virus or a 1:5 or 1:10 dilution. All macaques given 
undiluted virus became infected. Thirty-eight percent of macaques given a 1:5 dilution be-
came infected. To achieve a dose to infect all control animals a 1:2 dilution was chosen for 
the challenge dose. 
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Figure S1. Phase I hormone profiles for luteal phase inoculated macaques. [Top] OA5 
was inoculated with CEM mock control, and [Bottom] OCZ was inoculated with 
SIVsmB7. Animal menstrual cycling was tracked for at least one month prior to inocula-
tions to map out hormone profiles (data not shown). Dashed lines indicate start of twice 
daily, a.m. and p.m., inoculations. Dashed arrows represent individual inoculations as 
described in Methods. Inoculations were confirmed to take place approximately three 
days after the start of the luteal phase. Animals were euthanized (solid black arrow) and 
cervicovaginal tissue sections taken after the final estrogen/progesterone sample was 
measured. Axis scales were altered to highlight inflection of hormone profiles from follic-
ular to luteal phases. Estrogen (Black Line/Left Axis) Progesterone (Grey Line/Right Axis). 
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Figure S2. Estrogen/progesterone profiles for Phase II macaques. Estrogen (Grey/Left 
Axis) Progesterone (Dashed line/Right Axis). Horizontal dashed line indicates SIVmac251 
challenge as described in Methods. Macaques were targeted for challenge during the es-
trogen low, progesterone high luteal phase to avoid potential reduced SIV infectivity dur-
ing the follicular phase. Axes for M823, 4A1, 9F6, Av87 were modified to show change of 
menstrual stage. 
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Table S1. Target MHC I Genotypes for All Phase II Macaques* 
Macaque ID Study Arm MHC I** 
14R SIVsmB7 A01/B17 
3C5 SIVsmB7 A08 
5D5 SIVsmB7 A01/A02 
9D9 SIVsmB7 — 
9F6 SIVsmB7 A01 
AO76 SIVsmB7 — 
AR16 SIVsmB7 A01 
AV34 SIVsmB7 B01 
AV87 SIVsmB7 — 
AZ00 SIVsmB7 — 
M830 SIVsmB7 A02 
OE6 SIVsmB7 — 
15S CEM Mock Control 15S 
1D1 CEM Mock Control A08/B01 
2E6 CEM Mock Control A08 
31R CEM Mock Control — 
4A1 CEM Mock Control A08 
53O CEM Mock Control A08 
8D4 CEM Mock Control B01 
AJ80 CEM Mock Control A08 
AP41 CEM Mock Control A01 
M823 CEM Mock Control A01 
M847 CEM Mock Control A08 
SBR113 CEM Mock Control A08/B17 
* MHC I alleles tested for include A*01, A*02, A*08, A*11, B*01, B* 03, B*04, 
B*17, and B*08. A*01, B*08 and B*17 have been associated with control of 
SIV infection in Rhesus macaques [33–35]. 
** Dashes indicate that macaque had a genotype not assessed within our 
panel. 
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Figure S3. Results from selected cytokines tested in CVL Cytokine Multiplex Assay. 
Luminex 28-plex Assay (Invitrogen) was done according to manufacturer protocol on PBS 
lavage samples obtained within 1 week prior to macaque manipulation. Nearly half of the 
inflammatory cytokines tested were below the level of detection. Of those with detectable 
levels of cytokine there was no significant differences between macaques, including in-
flammatory mediators IL-1b, IFNγ, and IL-17 and chemokines IL-8 and CCL22. P-values 
were generated by two-sided Wilcoxon rank sum tests. 
  
A B D U L H A Q Q  E T  A L . ,  J O U R N A L  O F  A C Q U I R E D  I M M U N E  D E F I C I E N C Y  S Y N D R O M E S  6 5  (2 0 1 4 )  
26 
 
 
Figure S4. Proteomic analysis and comparison of SIVsmB7 and CEM control. (A) Pic-
ture of pellets after ultracentrifugation. Note the similarities in size and appearance of the 
pellets. (B) Silver staining of protein gels for CEM mock control and SIVsmB7 showed a 
high degree of similarity outside of five distinct bands in SIVsmB7 not found in CEM 
mock control. A colloidal stain was done to confirm the band differences. Once confirmed, 
those bands were excised for proteomic analysis. In each of these five bands, SIV gag pol-
yprotein or envelope was identified. (C) Top 15 proteins for SIVsmB7 and CEM mock 
control organized by SIVsmB7 abundance. The list contains only 19 proteins, showing the 
high degree of protein composition similarity between the two. The only truly notable 
protein not found in CEM mock control is SIV gag polyprotein, which is the most abun-
dant protein found in SIVsmB7. (D) Table showing the abundances of MHC protein frag-
ments detected in SIVsmB7 or CEM Mock control. Individual spectral counts were 
grouped according to MHC Class I or Class II for clarity. 
Method: SIVsmB7 is a virus-like particle (VLP) derived from a clone of a CEMx174 cell 
line infected with SIVsmH3 . Clone B7 cells have a single provirus integrated into their 
20th chromosome. SIVsmB7 is noninfectious due to a 1.6 kbp deletion, including inte-
grase, vif, vpr, and vpx genes [29]. To produce cell-free SIVsmB7 and CEM mock control, 
200,000 cells/ml of Clone B7 and uninfected CEMx174 cells were cultured in RPMI 1640 
(Mediatech, Inc.) supplemented with FBS. VLPs was purified on 20% (w/v) sucrose gra-
dient by ultra-centrifugation. Figure 1B illustrates individual pellets from CEM mock con-
trol and SIVsmB7 after supernatants are removed. The pellet was resuspended in RPMI 
1640 without supplementation. ELISA was done to measure P27 content. SIVsmB7 was 
diluted to a concentration of 500 µg P27 SIVsmB7 per 1 ml dose. CEMx174 dose was pre-
pared using identical techniques. 
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Table S2. Proteomic Analysis of Individual Differential Bands from SIVsmB7 and CEM 
mock control samples 
CEM Band 
Protein Name Coverage 
Spectral 
Count 
 SIVsmB7 Band 
Protein Name Coverage 
Spectral 
Count 
Band 1    Band 1   
FN1 protein 14.80% 29  Gag Polyprotein 60% 71 
Oleoyl-[acyl-carrier- 
protein] hydrolase 3.80% 6 
 
Filamin-A 15% 27 
Uncharacterized protein 2.20% 5  Desmoplakin 5.90% 17 
Dermcidin isoform 2 18.20% 3  Junction plakoglobin 11.90% 7 
Hornerin 4.50% 3  Desmoglein-1 9.10% 6 
Type I keratin 16; K16 8.50% 2 
 Ubiquitin/40S ribosomal 
protein S27a 44.40% 6 
Band 2    Band 2   
Minor Histocompatibil-
ity Antigen HA-2 23.00% 27 
 
Gag Polyprotein 59.80% 130 
Alpha Actin 4 27.60% 26 
 Minor histocompatibility 
HA-2 34.60% 51 
Kinesin-like protein 
KIF23 17.20% 15 
 Kinesin-like protein 
KIF23 28.10% 26 
Intercellular adhesion 
molecule 3 8.40% 7 
 
Alpha-actinin 26.50% 26 
cDNA FLJ56016, highly 
similar to C-1- 
tetrahydrofolate 
synthase, cytoplasmic 8.20% 9 
 
Major vault protein 23.60% 18 
Ubiquitin-like modifier-
activating enzyme 1 8.10% 7 
 Putative helicase 
MOV-10 16.10% 17 
Band 3    Band 3   
Glucose-6-phosphate 
isomerase 19.30% 14 
 
Gag Polyprotein 75.70% 397 
Pyruvate kinase 
isozymes M1/M2 30.10% 19 
 
Tubulin beta chain 55.20% 26 
cDNA FLJ61188, highly 
similar to Basigin 37.80% 13 
 cDNA FLJ37935 fis, clone 
CTONG2005290, highly 
similar to FASCIN 44.30% 23 
Uncharaterized protein 31.10% 14  Coronin-1A 41.40% 18 
cDNA FLJ37935 fis, clone 
CTONG2005290, highly 
similar to FASCIN 28.20% 14 
 
cDNA FLJ61188, highly 
similar to Basigin 37.80% 9 
Plastin-2 23.10% 13 
 cDNA FLJ32131 fis, 
highly similar to Tubulin 
alpha-ubiquitous chain 29.60% 6 
Band 4    Band 4   
Tubulin beta chain 41.20% 29  Gag Polyprotein 44.40% 41 
Alpha-enolase 39.60% 28  Alpha-Enolase 41.70% 39 
Coronin-1A 25.60% 16  Tubulin beta chain 45.90% 35 
Elongation factor 1-alpha 7.60% 5  Elongation factor 1-alpha 31.80% 26 
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APT synthast subunit 
beta, mitochondrial 15.10% 8 
 cDNA FLJ60299, highly 
similar to Rab GDP dis-
sociation inhibitor beta 43.90% 23 
Tubulin beta-2C chain 9.40% 5  Coronin-1A 20.00% 23 
Band 5    Band 5   
Ras-related protein 
Rab-35 15.90% 4 
 
Gag Polyprotein 37.70% 52 
RAB11B protein 19.30% 4 
 cDNA FLJ75480, highly 
similar to Human lac-
toferrin 22.50% 15 
60S ribosomal 
protein L18 
13.80% 3  Ras-related 
protein Rab-35 24.80% 8 
Uncharacterized protein 13.60% 3 
 Ras-related 
protein Rab-11A 34.70% 6 
B-lymphocyte 
antigen CD20 12.80% 3 
 
Elongation factor 1-alpha 9.70% 5 
S-9 (Fragment) 19.00% 3  40S ribosomal protein S9 19.6% 4 
 
Table S2. Results of individual band proteomic analysis for SIVsmB7 and CEM control. Top six 
proteins from each of the excised bands shown in figure 1 from CEM mock control [Left] and 
SIVsmB7 [Right]. As noted previously, SIV gag polyprotein was the dominant protein in each of 
those excised bands from SIVsmB7. The remaining proteins found in those bands were comparable 
to proteins identified from bands excised from CEM mock control taken from the same position in 
the CEM mock control lanes. Total coverage of the given protein is shown along with total spectral 
counts. 
